Compare Ascendis Pharma A/S (ASND) vs Open Text Corporation (OTEX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Open Text Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Open Text Corporation trades at $23.01 (market cap $5.56B). The key difference: Ascendis Pharma A/S is far larger — about 3.2× Open Text Corporation's market cap, and Open Text Corporation pays a 4.78% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | OTEX | |
|---|---|---|
Market Cap | $17.74B | $5.56B |
Sector | Health | Technology |
52-Week High | $277.18 | $39.69 |
52-Week Low | $163.32 | $20.01 |
Enterprise Value | $18.11B | $10.72B |
Dividend Yield | — | 4.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
OTEX trades at $23.01, up 0.17% today, with a bullish technical signal from moving averages and a consensus analyst price target of $29.75 implying 29% upside. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.994 exceeding expectations, and maintains robust profitability with a 73.06% gross margin. Recent developments include a $105 million investment in European AI and cloud expansion and the divestiture of non-core assets.
The outlook is positive given undervalued metrics like a P/E of 11.17 and EV/EBITDA of 6.7, alongside strategic focus on AI and cloud growth. Risks include execution challenges in integrating new investments and competitive pressures in the tech sector. Investor sentiment is cautiously optimistic, supported by analyst upgrades and institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
